Emulate Bio focuses on improving drug development in the pharmaceutical and healthcare sectors through its Organ-on-a-Chip technology. This technology mimics human biology more accurately than traditional methods, which helps researchers and pharmaceutical companies enhance the success rates of clinical trials and improve patient safety. The platform provided by Emulate includes instruments, consumables, and software that allow users to explore human biology in a flexible manner. This enables the development of safer and more effective drugs. Unlike competitors, Emulate not only sells its technology but also publishes research to aid in drug safety assessments, such as their work on Liver-Chip data. The main goal of Emulate Bio is to enhance human health and save lives by streamlining the drug development process.

Almanack Investment Partners

ALS Investment Fund

SciFi VC

Founders Fund

Starlight Ventures

ALS Finding a Cure

+ND Capital

OS Fund

Hansjörg Wyss

LabCorp

Techammer

ATEL Ventures

Qiming Venture Partners

Alumni Ventures

Perceptive Advisors

Northpond Ventures

National Institutes of Health

Biotechnology

Healthcare

Emulate

Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, announced the release of its new Chip-R1(TM) Rigid Chip, designed to minimize drug absorption and enhance biological modeling.

Emulate, Inc. introduces the Chip-R1(TM) Rigid Chip for improved biological modeling in ADME and toxicology applications

BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which researchers compared the performance of human Liver-Chips in predicting drug-induced liver injury (DILI) to those of animal in vivo models—the current industry standard—and primary human 3D hepatic spheroids. In addition to assessing and quantifying model performance, this study effectively qualifies the Emulate human Liver-Chip model against the guidelines defined by IQ MPS, an affiliate of the International Consortium for Innovation and Quality in Pharmaceutical Development. “This first-of-its-kind study demonstrates the Emulate human Liver-Chip can better predict drug safety than other methods for modeling liver toxicity,” said Jim Corbett, Chief Executive Officer of Emulate. "In light of these findings, the pharmaceutical industry and government agencies have a responsibility to both patients and researchers to bring efficient, accurate, and safe preclinical testing models—like Organ-Chips—into the drug development process.”

Emulate Publishes Landmark Study Validating Organ-On-A-Chip Technology For Predictive Toxicology In Preclinical Development

BOSTON--(BUSINESS WIRE)--Emulate, Inc., a leading provider of next-generation in vitro models, today announced the launch of its new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks, not months, as with animal models. This technology allows them to rapidly iterate on AAV design to optimize delivery of gene therapies and accelerate development. “The ability to more rapidly optimize AAV design using this application is a game-changer for the gene therapy industry,” said Emulate CEO Jim Corbett. “We are excited to offer this novel application to researchers in biopharmaceutical, academic, and government entities around the world who are exploring gene therapy as a potential to treat a wide range of diseases such as cancer, cystic fibrosis, heart disease, diabetes, and metabolic disease.”

Emulate Announces New Gene Therapy Application Enabling Accelerated Development Of Treatments For Genetic Diseases With Organ-On-A-Chip Technology

(Emulate) Organ-on-a-chip maker Emulate has launched an upgraded offering for researchers studying inflammatory bowel disease with its tissue model that helps illustrate how immune cells are activated and circulate through the body.

Emulate, Inc launches upgraded offering for researchers studying inflammatory bowel disease with tissue model

Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022.

Emulate, Inc recognized as Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022 on Mar 8th 22'.

Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.

Emulate Inc. launched Zoë-CM2 Culture Module on Nov 15th 21'.

Emulate, Inc., a leading provider of next generation in vitro models, today announced the close of an $82 million Series E financing round led by existing investor Northpond Ventures with additional participation from Perceptive Advisors.

NorthpondVentures invested into Emulate Inc. in $82M on Sep 7th 21'.

Emulate, Inc., a Boston, MA-based provider of next generation in vitro models, closed an $82m Series E financing round. The round, which brought total funding raised to date to nearly $225m, was led by existing investor Northpond Ventures with participation from Perceptive Advisors. The company intends to use the funds to continue to facilitate the creation of new human-relevant […]

Emulate Raises $82M in Series E Funding

In January, Emulate unveiled an ambitious plan to launch a suite of new organ-chip products over the next couple of years, each of them targeted to a specific research focus.

Emulate, Inc launched suite of new organ-chip products on Jan 1st 21'.

Check out new developments from Kiio, HealthMine, Emulate and Bind Benefits.

StartUPDATES: New developments from healthcare startups

Develops Organ-on-a-Chip technology for drug research

Emulate

Develops Organ-on-a-Chip technology for drug research

Emulate

Develops Organ-on-a-Chip technology for drug research

About

Simplify's Take

What believers are saying

What critics are saying

What makes Emulate unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

There are no jobs for Emulate right now.